Phenotypic and Genotypic Characteristics of Neisseria meningitidis Disease-Causing Strains in Argentina, 2010

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Sorhouet Pereira, Cecilia ^a   Efron, Adriana ^a   Gagetti, Paula ^a   Faccone, Diego ^a   Regueira, Mabel ^a   Corso, Alejandra ^a   Gabastou, Jean Marc ^b   Ibarz Pavón, Ana Belén ^b  

^a Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^b PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE;

ARGENTINA; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SEROTYPE;

ANTI-INFECTIVE AGENTS; ARGENTINA; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MENINGITIS, MENINGOCOCCAL; MICROBIAL SENSITIVITY TESTS; NEISSERIA MENINGITIDIS; PHENOTYPE;

EID: 84874610379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058065     Document Type: Article

References (48)

1. Stephens DS, (2007) Conquering the meningococcus. FEMS Microbiol Rev 31: 3-14.
2. Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J, (2001) Meningococcal disease. New England Journal of Medicine 344: 1378-1388.
3. Gabastou JM, Agudelo CI, Brandileone MC, Castaneda E, de Lemos AP, et al. (2008) [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Rev Panam Salud Publica 24: 1-15.
4. Castaneda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, et al. (2009) Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 28: e265-270.
5. OPS (2011) Informe Regional de SIREVA II: datos por país y por grupo de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasivos 2010. Washington D.C.: OPS. 315 p.
6. Chiavetta L, Chavez E, Ruzic A, Mollerach M, Regueira M, (2007) [Surveillance of Neisseria meningitidis in Argentina, 1993-2005: distribution of serogroups, serotypes and serosubtypes isolated from invasive disease]. Rev Argent Microbiol 39: 21-27.
7. Ibarz-Pavon AB, Lemos AP, Gorla MC, Regueira M, Group SW 2nd,et al. Laboratory-Based Surveillance of Neisseria meningitidis isolates from Disease Cases in Latin American and Caribbean Countries, SIREVA II 2006-2010. PLoS One 7: e44102.
8. Panatto D, Amicizia D, Lai PL, Gasparini R, (2011) Neisseria meningitidis B vaccines. Expert Rev Vaccines 10: 1337-1351.
9. Jacobsson S, Hedberg ST, Molling P, Unemo M, Comanducci M, et al. (2009) Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27: 1579-1584.
10. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
11. Thompson EA, Feavers IM, Maiden MC, (2003) Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149: 1849-1858.
12. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, et al. (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72: 5955-5962.
13. Brehony C, Wilson DJ, Maiden MC, (2009) Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155: 4155-4169.
14. Moriel DG, Scarselli M, Serino L, Mora M, Rappuoli R, et al. (2008) Genome-based vaccine development: a short cut for the future. Hum Vaccin 4: 184-188.
15. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.
16. Abdillahi H, Poolman JT, (1987) Wole-cell ELISA for Typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiology Letters 48: 367-371.
17. CLSI (2010) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Eighth Edition. Approved Standard. Document M7-A8.
18. Corso A, Faccone D, Miranda M, Rodriguez M, Regueira M, et al. (2005) Emergence of Neisseria meningitidis with decreased susceptibility to ciprofloxacin in Argentina. J Antimicrob Chemother 55: 596-597.
19. Taha MK, Achtman M, Alonso JM, Greenwood B, Ramsay M, et al. (2000) Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 356: 2159.
20. Taha MK, Giorgini D, Ducos-Galand M, Alonso JM, (2004) Continuing diversification of Neisseria meningitidisW135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 42: 4158-4163.
21. Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, et al. (2009) W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 47: 1979-1980.
22. Barroso DE, Rebelo MC, (2007) Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil. Mem Inst Oswaldo Cruz 102: 773-775.
23. Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC, et al. (2008) High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect 57: 324-331.
24. Ministerio de Salud, Gobierno de Chile (2012). Available: http://epi.minsal.cl/epi/html/bolets/reportes/Meningitis/W135_SE522012.pdf.Accessed 2013 Feb 6.
25. OPS (2012) Informe Regional de SIREVA II: datos por país y por grupo de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasivos 2011. Washington D.C.: OPS. 315 p.
26. Sorhouet Pereira C, Regueira M, Mollerach M, (2008) PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 57: 338-342.
27. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, et al. (2007) A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31: 27-36.
28. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, et al. (2009) Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 47: 3577-3585.
29. de Filippis I, de Lemos AP, Hostetler JB, Wollenberg K, Sacchi CT, et al. (2012) Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil. PLoS One 7: e33016.
30. Racloz VN, Luiz SJ, (2010) The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 10: 175.
31. Gorla MC, de Lemos AP, Quaresma M, Vilasboas R, Marques O, et al. (2011) Phenotypic and molecular characterization of serogroup C Neisseria meningitidis associated with an outbreak in Bahia, Brazil. Enferm Infecc Microbiol Clin 30: 56-59.
32. Iser BP, Lima HC, de Moraes C, de Almeida RP, Watanabe LT, et al. (2011) Outbreak of Neisseria meningitidis C in workers at a large food-processing plant in Brazil: challenges of controlling disease spread to the larger community. Epidemiol Infect 140: 906-915.
33. Salisbury D (2001) Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 37: S34-36; discussion 37.
34. Claus H, Maiden MC, Maag R, Frosch M, Vogel U, (2002) Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148: 1813-1819.
35. Hoang LM, Thomas E, Tyler S, Pollard AJ, Stephens G, et al. (2005) Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 40: e38-42.
36. Vogel U, Claus H, von Muller L, Bunjes D, Elias J, et al. (2004) Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J Clin Microbiol 42: 2898-2901.
37. Johswich KO, Zhou J, Law DK, St Michael F, McCaw SE, et al. (2012) Invasive potential of non-encapsulated disease isolates of Neisseria meningitidis. Infect Immun.
38. Findlow H, Vogel U, Mueller JE, Curry A, Njanpop-Lafourcade BM, et al. (2007) Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis 195: 1071-1077.
39. Vazquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, et al. (2003) Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 47: 3430-3434.
40. Enriquez R, Abad R, Salcedo C, Perez S, Vazquez JA, (2008) Fluoroquinolone resistance in Neisseria meningitidis in Spain. J Antimicrob Chemother 61: 286-290.
41. Corso APG, Sorhouet Pereira C, Efron A, Rodriguez M, Faccone D, et al. (2009) National Surveillance on Antimicrobial Resistance and Serogroups of Neisseria meningitidisIsolates causing Invasive Disease in Argentina: 1998-2008. Buenos Aires, Argentina. 18 al 22 de Noviembre.
42. Castanheira M, Deshpande LM, Jones RN, Farrell DJ, (2012) Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. Diagn Microbiol Infect Dis 72: 263-266.
43. Alcala B, Salcedo C, de la Fuente L, Arreaza L, Uria MJ, et al. (2004) Neisseria meningitidisshowing decreased susceptibility to ciprofloxacin: first report in Spain. J Antimicrob Chemother 53: 409.
44. Mehta G, Goyal R, (2007) Emerging fluoroquinolone resistance in Neisseria meningitidis in India: cause for concern. J Antimicrob Chemother 59: 329-330.
45. Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, et al. (2007) Ciprofloxacin-resistant Neisseriameningitidis, Delhi, India. Emerg Infect Dis 13: 1614-1616.
46. MMWR (2008) Emergence of Fluoroquinolone-Resistant Neisseria meningitidis- Minnesota and North Dakota, 2007-2008. MMWR Weekly 57: 173-175.
47. Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, et al. (2009) Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 360: 886-892.
48. Skoczynska A, Alonso JM, Taha MK, (2008) Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg Infect Dis 14: 1322-1323.